VarmX Partners with CSL to Advance Novel Coagulation Treatment
Wednesday, September 17, 2025
VarmX has entered into a strategic collaboration with CSL to support the development of its lead investigational therapy, VMX-C001.
VMX-C001 is a recombinant modified Factor X protein, delivered as a rapid single dose to bypass anticoagulation activity and restore clotting. It is designed to be effective across all FXa DOACs, can be used alongside common anticoagulants such as heparin, and may carry no added risk of thrombosis.
The therapy is designed to restore blood clotting in patients on Factor Xa direct oral anticoagulants (FXa DOACs) who face severe bleeding or require urgent surgery.
As part of the agreement, CSL will fully fund the global Phase 3 EquilibriX-S trial of VMX-C001, along with late-stage product development, manufacturing, and pre-launch commercial activities. CSL has also secured an exclusive option agreement with VarmX shareholders to acquire the company.
Under the terms, CSL will make an upfront payment of USD 117 million for the option, with the right to exercise it following Phase 3 results. Additional payments include up to USD 388 million linked to development and regulatory milestones, and as much as USD 1.7 billion based on sales-related achievements.
The therapy has been granted Fast Track Designation by the US Food and Drug Administration, enabling it to move directly into a single Phase 3 trial. Commercial launch is anticipated in 2029.
By 2030, around 30 million patients in the US, Europe, and Japan are expected to be on FXa DOACs for conditions such as atrial fibrillation and deep vein thrombosis.
Source: varmx.com
